JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma
Yanagita, Kengo; Nagashio, Ryo; Ryuge, Shinichiro; Katono, Ken; Jiang, Shi-Xu; Tsuchiya, Benio; Nakashima, Hiroyasu; Fukuda, Eriko; Goshima, Naoki; Saegusa, Makoto; Satoh, Yukitoshi; Masuda, Noriyuki; Sato, Yuichi;
  PDF(new window)
 Abstract
Background: Identification of predictive markers for the efficacy of platinum-based chemotherapy is necessary to improve the quality of the life of cancer patients. Materials and Methods: We detected proteins recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma (AC) evaluated as showing progressive disease (PD) or a partial response (PR) after cisplatin-based chemotherapy by proteomic analysis. Then, the levels of the candidate autoantibodies in the pretreated serum were validated by dot-blot analysis for 22 AC patients who received platinum-based chemotherapy, and the expression of identified proteins was immunohistochemically analyzed in 40 AC biopsy specimens. Results: An autoantibody against galectin-3 (Gal-3) was detected in pretreated sera from an AC patient with PD. Serum IgG levels of anti-Gal-3 autoantibody were significantly higher in patients evaluated with PD than in those with PR and stable disease (SD) (p
 Keywords
Galectin-3;autoantibody;lung adenocarcinoma;predictive marker; gel electrophoresis;
 Language
English
 Cited by
 References
1.
Balan V, Nangia-Makker P, Jung YS, et al (2010). Galectin-3: a novel substrate for c-Abl kinase. Biochem Biophys Acta, 1803, 1198-205. crossref(new window)

2.
Chang A (2011). Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer, 7, 3-10.

3.
Chiu CG, Strugnell SS, Griffith OL, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol, 176, 2067-81.

4.
Fernandez-Madrid F, Tang N, Alansari H, et al (2004). Autoantibodies to Annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res, 64, 5089-96. crossref(new window)

5.
Fukumori T, Oka N, Takenaka Y, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res, 66, 3114-9.

6.
Gonzalez V M, Fuertes M A, Alonso C, et al (2001). Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol, 59, 657-63.

7.
Goshima N, Kawamura Y, Fukumoto A, et al. Human protein factory for converting the transcriptome into an in vitroexpressed proteome. Nat Methods, 5, 1011-7.

8.
Hanash S (2003). Harnessing immunity for cancer marker discovery. Nat Biotechnol, 21, 37-8. crossref(new window)

9.
Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66. crossref(new window)

10.
Kageyama T, Nagashio R, Ryuge S, et al (2011). HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer. Asian Pac J Cancer Prev, 12, 3457-63.

11.
Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-5. crossref(new window)

12.
Le Naour F, Brichory F, Misek DE, et al (2002). A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics, 1, 197-203. crossref(new window)

13.
Nagashio R, Sato Y, Jiang SX, et al (2008). Detection of tumorspecific autoantibodies in sera of patients with lung cancer. Lung Cancer, 62, 364-73. crossref(new window)

14.
Oishi T, Itamochi H, Kigawa J, et al (2007). Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer, 17, 1040-6. crossref(new window)

15.
Park SH, Min HS, Kim B, et al (2008). Galectin-3: a useful biomarker for differential diagnosis of brain tumors. Neuropathology, 28, 497-506. crossref(new window)

16.
Pepe C, Hasan B, Winton TL, et al (2007). Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 25, 1553-61. crossref(new window)

17.
Perng RP, Yang CH, Chen YM, et al (2008). High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer, 62, 78-84. crossref(new window)

18.
Saussez S, Decaestecker C, Mahillon V, et al (2008). Galectin-3 up-regulation during tumor progression in head and neck cancer. Laryngoscope, 118, 1583-90. crossref(new window)

19.
Stewart DJ (2007). Mechanism of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol, 63, 12-31. crossref(new window)

20.
Tsuboi K, Shimura T, Masuda N, et al (2007). Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res, 27, 2289-96.

21.
Vural B, Chen LC, Saip P, et al (2005). Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer, 103, 2575-83. crossref(new window)

22.
Watanabe H, Yamamoto S, Kunitoh H, et al (2003). Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci, 94, 1015-20. crossref(new window)

23.
Wongkham S, Junking M, Wongkham C, et al (2009). Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. Cancer Sci, 100, 2077-84. crossref(new window)

24.
Xia Q, Kong XT, Zhang GA, et al (2005). Proteomicsbased identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun, 330, 26-32.

25.
Yagihashi A, Asanuma K, Kobayashi D, et al (2005). Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer, 48, 217-21. crossref(new window)